Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The scientific rationale for developing taxoids

M Aapro1

  • 1European Institute of Oncology, Milan, Italy.

Anti-Cancer Drugs
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development.

ESMO open·2025
Same author

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

ESMO open·2024
Same author

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2023
Same author

Nutrition education in medical schools (NEMS) project: Promoting clinical nutrition in medical schools - Perspectives from different actors.

Clinical nutrition (Edinburgh, Scotland)·2022
Same author

Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries.

ESMO open·2021
Same journal

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.

Anti-cancer drugs·2026
Same journal

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Anti-cancer drugs·2026
Same journal

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.

Anti-cancer drugs·2026
Same journal

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Anti-cancer drugs·2026
Same journal

Drug repurposing of liver cancer based on multimodal neural network and virtual screening.

Anti-cancer drugs·2026
Same journal

Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.

Anti-cancer drugs·2026
See all related articles

Docetaxel (Taxotere) is a more potent antitumour drug than paclitaxel (Taxol), demonstrating superior microtubule stabilization, cell uptake, and intracellular retention. Its efficacy in preclinical models and clinical trials supports its use against solid tumours.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Taxoid drugs, including docetaxel and paclitaxel, are novel antitumour agents.
  • These drugs function by modulating microtubule dynamics, promoting assembly and inhibiting disassembly.

Purpose of the Study:

  • To compare the in vitro and in vivo efficacy of docetaxel and paclitaxel.
  • To evaluate the pharmacokinetic and pharmacodynamic properties of docetaxel relative to paclitaxel.
  • To assess the clinical activity and potential combination strategies for docetaxel.

Main Methods:

  • In vitro studies assessing microtubule assembly and cell cytotoxicity.
  • In vitro cell uptake and intracellular retention assays.
  • Review of clinical data on docetaxel activity and toxicity.

Related Experiment Videos

Main Results:

  • Docetaxel exhibits greater potency in microtubule formation and stabilization compared to paclitaxel in vitro.
  • Docetaxel demonstrates higher cellular uptake and prolonged intracellular retention.
  • Docetaxel is a more potent antitumour agent in preclinical models and shows significant clinical activity in solid tumours.
  • Cytotoxic concentrations of docetaxel align with clinically achieved plasma levels, and dose-limiting neutropenia occurs at lower doses than paclitaxel.

Conclusions:

  • Docetaxel is a more potent antitumour agent than paclitaxel, supported by in vitro and clinical data.
  • Docetaxel's pharmacokinetic and pharmacodynamic profile contributes to its enhanced efficacy.
  • Combination therapy with docetaxel is under active investigation for synergistic effects and manageable toxicity.